

Cleansing Notice under section 708A(5)(e) of the Corporations Act

This notice is given by Microba Life Sciences Limited (ASX : MAP) (**Microba** or **Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

On 19 October 2023, Microba announced it had signed a share purchase agreement for the acquisition of 100% of the issued share capital in UK registered company, Invivo Clinical Limited (**Invivo**) (**Acquisition**).

As announced on 6 December 2023, the Acquisition has now completed and 13,141,578 ordinary shares (**Consideration Shares**) have been issued to the shareholders of Invivo.

The Consideration Shares were issued today, on 6 December 2023 and an Appendix 2A has been lodged with the ASX for quotation of those Consideration Shares. Details of the Consideration Shares issue is provided below:

Class of Securities	The Consideration Shares are fully paid ordinary shares
Total number of Consideration Shares	13,141,578
Date of the issue	6 December 2023
Voluntary Escrow	The Consideration Shares are subject to voluntary escrow until 6 December 2025
ASX Code of the securities	ASX: MAP

In accordance with section 708A(6) of the *Corporations Act* (Cth) (**Corporations Act**) Microba gives notice that:

- The Consideration Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- This notice is being given under section 708A(5)(e) of the Corporations Act;
- As of the date of this notice, the Company has complied with:
 - The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - Sections 674 and 674A of the Corporations Act; and
- As of the date of this notice, with the exception of the below, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

By way of update, further to the ASX Announcements on 29 March 2023, 28 June 2023 and 25 August 2023, the Company advises that it has now received data in respect to its IBD Phase I Clinical Trial. The Company will make an announcement to the ASX as soon as the review and analysis of the data is completed.

Authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.